ACell launches two new wound management devices

ACell, Inc. today announced the introduction of two new wound management devices: Cytal Wound Matrix 3-Layer and Cytal Wound Matrix 6-Layer. These devices are intended for the management of partial- and full-thickness wounds including pressure ulcers, venous ulcers, diabetic ulcers, tunneled wounds, traumatic wounds, and surgical wounds.

"Cytal expands ACell's presence in the rapidly expanding wound care market, and complements our portfolio of wound management devices," said Kyle Kerbawy, Chairman of the Board. "Everyone at ACell is focused on offering physicians and their patients effective clinical options, and Cytal addresses an unmet need in chronic and acute wound management."

Cytal wound matrices allow for prolonged persistence of ACell's proprietary Urinary Bladder Matrix (UBM) in the wound, providing for a robust scaffold for cell infiltration and may reduce need for follow up care. The pre-fenestrated design is highly conformable in irregular wound beds and supports effective fluid management. Cytal will be available in three sizes in both 3- and 6-layer configurations.

ACell's wound management portfolio also includes MicroMatrix®, MatriStem® Wound Matrix, MatriStem Multilayer Wound Matrix, and MatriStem Burn Matrix. ACell also manufactures and distributes a line of surgical devices including various MatriStem® Surgical Matrix sheets and MatriStem Pelvic Floor Matrix.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study uncovers diversity of cancer-associated fibroblasts in skin cancer